HMMR and Miyoshi myopathy: HLA-A2-restricted epitopes within RHAMM have been identified [61], and the most robust one, which was designated R3, was tested in clinical peptide vaccination trials in patients with acute myeloid leukemia, myelodysplastic syndrome, and MM.